NEW
YORK, March 10, 2025 /PRNewswire/ -- Baird
Medical Investment Holdings Ltd. (NASDAQ:
BDMD) ("Baird Medical" or the "Company"), a forward-thinking
medical device company specializing in AI-powered surgical robotics
and next-generation surgical instruments, and a global leader in
microwave ablation (MWA) technology, has received
regulatory approval from the Indonesian Ministry of Health
(Kementerian Kesehatan Republik Indonesia). This approval includes the Great
Wall Microwave Therapeutic Instrument and the Great Wall Disposable
Microwave Ablation Needle, laying the foundation for Baird Medical
to introduce its advanced minimally invasive treatment solutions
across Indonesia.
"This regulatory approval marks a significant step in our global
strategic expansion and underscores our commitment to improving
patient care with cutting-edge, minimally invasive technologies,"
said Haimei Wu, Chairwoman of Baird Medical. "We look forward
to collaborating with Indonesian healthcare providers and
supporting them with innovative solutions that enhance precision,
safety, and patient outcomes.
Microwave ablation is a highly effective, minimally invasive
procedure that uses targeted microwave energy to destroy abnormal
tissue with minimal impact on surrounding areas. Recognized for its
precision and faster recovery times, MWA is widely used for
treating conditions such as thyroid nodules and tumors.
With this regulatory milestone, Baird Medical is set to expand
its distribution network and collaborate with key medical
institutions in Indonesia,
reinforcing its commitment to bringing next-generation medical
solutions to emerging markets.
About Baird Medical
Baird Medical is a forward-thinking medical device company
specializing in minimally invasive diagnostics and treatment. It is
dedicated to the research and development of AI-powered surgical
robotic systems and innovative minimally invasive surgical
instruments. Our mission is to enhance patient outcomes through
precision technology and advanced diagnostic solutions. The
company's technological roadmap will fully integrate breakthrough
innovations from the open-source AI community—leveraging
cutting-edge inference models such as Deepseek and Grok3, while
fostering strategic collaborations with leading academic
institutions. Our vision extends beyond surgical assistance, aiming
to develop intelligent systems that proactively guide diagnostic
decisions and preventive healthcare strategies. As an FDA
510(k)-certified medical device company, Baird Medical has deployed
its solutions in over 30 prestigious hospitals and clinics across
the United States, including Johns
Hopkins Hospital, Tulane Medical Center, Weill Cornell Medicine,
and Columbia University Medical Center.
Baird Medical is also the market leader in China in thyroid microwave ablation devices
and consumables. Meanwhile, the company's minimally invasive
treatment products are gradually expanding their commercial
presence in over 20 countries worldwide.
Forward-Looking Statements
This press release includes certain statements that are not
historical facts but are forward-looking statements for purposes of
the safe harbor provisions under the United States Private
Securities Litigation Reform Act of 1995. Forward-looking
statements generally relate to future events or Baird Medical's
future financial or operating performance. In some cases, you can
identify forward-looking statements by terminology such as "may",
"could", "should", "expect", "intend", "might", "will", "estimate",
"anticipate", "believe", "budget", "forecast", "intend", "plan",
"potential", "predict", "potential" or "continue", or the negatives
of these terms or variations of them or similar terminology.
Forward-looking statements are subject to risks, uncertainties, and
other factors which could cause actual results to differ materially
from those expressed or implied by such forward-looking statements.
These forward-looking statements are based upon estimates and
assumptions that, while considered reasonable by Baird Medical and
its management, are inherently uncertain. New risks and
uncertainties may emerge from time to time, and it is not possible
to predict all risks and uncertainties. You should not place undue
reliance on forward-looking statements in this press release, which
speak only as of the date they are made and are qualified in their
entirety by reference to the cautionary statements herein. Baird
Medical does not undertake any duty to update these forward-looking
statements.
Actual results may vary materially from those expressed or
implied by forward-looking statements based on a number of factors,
including, without limitation: (1) the risk that Baird Medical may
not be successful in expanding its business in China or the United
States; (2) changes in general economic conditions; (3)
regulatory conditions and developments; (4) changes in applicable
laws or regulations; (5) the nature, cost and outcome of pending
and future litigation and other legal proceedings instituted
against Baird Medical or others; and (5) other risks and
uncertainties from time to time described in the Registration
Statement relating to the Business Combination and the transition
report, including those listed under the sections titled "Risk
Factors" therein, and in ExcelFin's other filings with the SEC.
The foregoing list of factors is not exclusive. Additional
information concerning certain of these and other risk factors is
contained in ExcelFin's most recent filings with the SEC and in the
Registration Statement described above filed by Baird Medical in
connection with its business combination with ExcelFin. All
subsequent written and oral forward-looking statements concerning
Baird Medical, the business combination described herein or other
matters attributable to Baird Medical or any person acting on its
behalf are expressly qualified in their entirety by the cautionary
statements above. Readers are cautioned not to place undue reliance
upon any forward-looking statements, which speak only as of the
date made. Baird Medical expressly disclaims any obligations or
undertaking to release publicly any updates or revisions to any
forward-looking statements contained herein to reflect any change
in their expectations with respect thereto or any change in events,
conditions or circumstances on which any statement is based.
Contact:
Eric Huang, PR Liaison
Baird Medical Investment Holdings Ltd.
Phone: +1 (888) 508-6228
Email: ir@bairdmed.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/baird-medical-secures-indonesian-regulatory-approval-for-microwave-ablation-technology-302396592.html
SOURCE BDMD
